TNF and neoplasm: In a Phase I clinical trial, gold-NP conjugated tumor necrosis factor-α (TNF-α), namely CYT-6091, significantly inhibited tumor growth and reduced interstitial fluid pressure when combined with radiation (12/20 Gy) in breast cancer and neck cancer models [51].